|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
84,190,000 |
Market
Cap: |
10.38(B) |
Last
Volume: |
427,350 |
Avg
Vol: |
426,189 |
52
Week Range: |
$67.31 - $141.53 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 983 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
143,757 |
247,027 |
Total Buy Value |
$0 |
$0 |
$13,295,068 |
$24,257,422 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
5 |
7 |
Total Shares Sold |
4,396 |
27,731 |
42,731 |
43,589 |
Total Sell Value |
$602,450 |
$3,499,041 |
$5,099,841 |
$5,194,152 |
Total People Sold |
2 |
7 |
7 |
7 |
Total Sell Transactions |
2 |
7 |
8 |
9 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Black Bear Offshore Master Fund Lp |
10% Owner |
|
2009-05-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,914,211 |
|
- |
|
Goolsbee William Alden |
Director |
|
2009-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
|
- |
|
Price Ben Gil |
Director |
|
2009-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
86,982 |
|
- |
|
Forrest K Michael |
Outside Director |
|
2009-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,000 |
|
- |
|
Casey Michael D |
Director |
|
2009-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Hodgman John |
Director |
|
2009-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Price Ben Gil |
Director |
|
2009-03-16 |
4 |
B |
$0.67 |
$13,703 |
D/D |
20,400 |
81,982 |
2.39 |
- |
|
Price Ben Gil |
Director |
|
2009-03-13 |
4 |
B |
$0.65 |
$19,377 |
D/D |
30,000 |
61,582 |
2.39 |
- |
|
Boyle J David Ii |
CFO |
|
2009-03-13 |
4 |
B |
$0.64 |
$12,145 |
D/D |
19,000 |
65,282 |
2.74 |
- |
|
Kole Ryszard |
SVP/Discovery Research |
|
2009-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
21,432 |
1,862,926 |
|
- |
|
Hudson Leslie |
CEO |
|
2009-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
124,324 |
457,324 |
|
- |
|
Boyle J David Ii |
CFO |
|
2009-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
46,282 |
46,282 |
|
- |
|
Iversen Patrick L |
Sr VP of Research & Devlopment |
|
2009-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
31,545 |
86,303 |
|
- |
|
Weller Dwight D |
Sr. VP Chemistry & Mfg. |
|
2009-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
28,919 |
314,741 |
|
- |
|
Shrewsbury Stephen B |
SVP/Regulatory Affairs |
|
2009-01-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
|
- |
|
Kole Ryszard |
Senior Vice President |
|
2008-09-03 |
4 |
AS |
$1.12 |
$42,746 |
D/D |
(38,200) |
1,841,494 |
|
- |
|
Kole Ryszard |
Senior Vice President |
|
2008-09-02 |
4 |
AS |
$1.13 |
$69,587 |
D/D |
(61,800) |
1,879,694 |
|
- |
|
Price Ben Gil |
Director |
|
2008-08-15 |
4 |
B |
$1.22 |
$8,030 |
D/D |
6,582 |
31,582 |
2.39 |
- |
|
Kole Ryszard |
Senior Vice President |
|
2008-06-03 |
4 |
S |
$1.40 |
$5,668 |
D/D |
(4,048) |
1,941,494 |
|
- |
|
Kole Ryszard |
SENIOR VICE PRESIDENT |
|
2008-05-20 |
4 |
AS |
$1.56 |
$23,474 |
D/D |
(15,000) |
1,945,542 |
|
- |
|
Kole Ryszard |
Senior Vice PresidentOfficer |
|
2008-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,960,542 |
|
- |
|
Haywood George Weaver |
10% Owner |
|
2008-03-31 |
4 |
B |
$1.83 |
$286,254 |
I/I |
156,423 |
1,426,953 |
1.5 |
- |
|
Haywood George Weaver |
10% Owner |
|
2008-03-27 |
4 |
B |
$1.75 |
$48,724 |
D/D |
27,842 |
7,333,717 |
2.37 |
- |
|
Haywood George Weaver |
10% Owner |
|
2008-03-26 |
4 |
B |
$1.74 |
$174,000 |
I/I |
100,000 |
1,270,530 |
1.5 |
- |
|
Haywood George Weaver |
10% Owner |
|
2008-03-25 |
4 |
B |
$1.72 |
$172,000 |
I/I |
100,000 |
1,170,530 |
1.5 |
- |
|
524 Records found
|
|
Page 19 of 21 |
|
|